2024年美国临床肿瘤学会（ASCO）年会将于2024年5月31日至6月4日在美国伊利诺伊州芝加哥举行。目前，ASCO官网已公布了本次会议的日程和摘要题目。【肿瘤资讯】特别整理了泌尿系统肿瘤的重磅研究，与读者分享。
前列腺癌
摘要号：LBA5000
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).
卡巴他赛联合阿比特龙 vs.单独阿比特龙治疗多西他赛后广泛期疾病的随机试验：ECOG-ACRIN癌症研究组（EA8153）的CHAARTED2试验
讲者： Christos Kyriakopoulos/University of Wisconsin Carbone Cancer Center
摘要号：LBA5002
A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.
一项针对低风险前列腺癌患者，在期待性管理中使用二甲双胍减少疾病进展的随机、双盲、安慰剂对照试验：MAST（二甲双胍主动监测试验）研究
讲者：Neil Fleshner/Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network
摘要号：LBA5004
MANCAN2: A multicentre randomised controlled trial of self-help cognitive behavioural therapy (CBT) to manage hot flush and night sweats (HFNS) symptoms in patients with prostate cancer receiving androgen deprivation therapy (ADT). MANCAN2：一项多中心随机对照试验，采用自助式认知行为疗法（CBT）来管理接受雄激素剥夺治疗的前列腺癌患者的潮热和夜间盗汗症状
讲者：Simon Crabb/ Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust
摘要号：LBA5014
Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.
随机TRANSFORMER试验中，双极雄激素治疗和恩扎卢胺疗效差异的血液标志物
讲者：Samuel Denmeade/Johns Hopkins University School of Medicine
摘要号：5001
CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.
CYCLONE 2：一项关于阿贝西利联合阿比特龙治疗转移性去势抵抗性前列腺癌的3期研究
讲者：Matthew Smith/Massachusetts General Hospital Cancer Center and Harvard Medical School
摘要号：5003
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).
多西他赛未治疗的转移性去势抵抗性前列腺癌患者进行的[177Lu]Lu-PSMA-617的3期研究中，健康相关的生活质量和疼痛（PSMAfore）
讲者：Karim Fizazi/Institut Gustave Roussy, University of Paris-Saclay
摘要号：5005
EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).
EMBARK事后分析，研究治疗暂停对健康相关的生活质量的影响
讲者：Stephen Freedland/Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Durham VA Medical Center
摘要号：5006
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
来自PRESTO（AFT-19）的健康相关的生活质量结果，一项针对高风险生化复发的去势敏感前列腺癌患者加强雄激素阻断的3期随机试验
讲者：Ronald Chen/University of Kansas Medical Center
摘要号：5007
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).
一个基于临床遗传循环肿瘤DNA的预后模型，用于预测接受强效雄激素受体抑制治疗的转移性去势抵抗性前列腺癌男性患者的总生存期（Alliance）
讲者：Susan Halabi/Department of Biostatistics and Bioinformatics, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine
摘要号：5008
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
接受177Lu-PSMA-617治疗的多西他赛未治疗的mCRPC患者中的基线ctDNA分析及其与PSMAfore中ARPI变化结果的关联
讲者：Johann De Bono/The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
摘要号：10500
Effect of polygenic risk score for clinically significant prostate cancer in a screening program: The BARCODE 1 study results.
筛查项目中多基因风险评分对有临床意义前列腺癌的影响：BARCODE 1研究结果
讲者：Ros Eeles/Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
尿路上皮癌/膀胱癌
摘要号：LBA4517
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.
围手术期sacituzumab govitecan（SG）单独或联合pembrolizumab（Pembro）治疗肌层浸润性尿路上皮膀胱癌（MIBC）患者：SURE-01/02中期结果
讲者：Antonio Cigliola/Medical Oncology Department, IRCCS San Raffaele Hospital
摘要号：4501
Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).
免疫增强营养对根治性膀胱切除术结果的影响：随机3期双盲临床试验（S1600）的主要结果
讲者：Jill Hamilton-Reeves/University of Kansas Medical Center
摘要号：4502
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
在之前未接受治疗的局部晚期或转移性尿路上皮癌患者中，enfortumab vedotin联合帕博利珠单抗（EV+P）vs. 铂类化疗的随机3期试验的患者报告结果
讲者：Shilpa Gupta/ Taussig Cancer Institute, Cleveland Clinic
摘要号：4503
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
在局部晚期或转移性尿路上皮癌患者中，enfortumab vedotin暴露对结果的影响
讲者：Daniel Petrylak/ Yale School of Medicine
摘要号：4509
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 tria
从CheckMate 901试验中，对纳武利尤单抗 + 吉西他滨-铂类 vs.单独吉西他滨-铂类的完全应答者的特征，以及仅有淋巴结转移的尿路上皮癌患者的特征进行描述
讲者：Matt Galsky/ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
肾癌
摘要号：LBA5500
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
BrUOG 354的最终结果：纳武利尤单抗单独或与伊匹木单抗联合治疗卵巢和其他肾外透明细胞癌患者的随机II期试验
讲者：Don Dizon/Lifespan Cancer Institute, Rhode Island Hospital
摘要号：4504
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
来自3期CLEAR试验的晚期肾细胞癌患者的生物标志物分析
讲者：Robert Motzer/Memorial Sloan Kettering Cancer Center
摘要号：4505
Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC). 。
在3期KEYNOTE-426研究中，对帕博利珠单抗联合阿昔替尼vs. 舒尼替尼治疗晚期肾细胞癌的生物标志物分析。
讲者：Brian Rini/Vanderbilt-Ingram Cancer Center
摘要号：4506
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.
在IMmotion010中进行的循环肾脏损伤分子-1生物标志物分析：一项对切除后复发风险增加的肾细胞癌患者进行的随机3期研究，比较辅助性阿替利珠单抗与安慰剂
讲者：Laurence Albiges/Gustave Roussy, Université Paris Saclay
摘要号：4507
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).
部分总生存期：在CheckMate 9ER中对4年以上生存状态的全面分析，比较一线纳武利尤单抗联合卡博替尼与舒尼替尼治疗晚期肾细胞癌
讲者：Charlene Mantia/Dana-Farber Cancer Institute
摘要号：4508
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
阿维鲁单抗+阿昔替尼 vs. 舒尼替尼在晚期肾细胞癌患者中的比较：来自JAVELIN Renal 101 3期试验的最终总生存期分析
讲者：Robert Motzer/Memorial Sloan Kettering Cancer Center
排版编辑：肿瘤资讯-cy
苏公网安备32059002004080号
